Topics

Lilly’s solanezumab fails to meet objective in phase 2/3 DIAN-TU Study

07:04 EST 11 Feb 2020 | Pharmaceutical Business Review

Based on the result of the primary endpoint, Lilly has dropped its plan to pursue regulatory submission for solanezumab in people having dominantly inherited Alzheimer’s disease (DIAD) or

The post Lilly’s solanezumab fails to meet objective in phase 2/3 DIAN-TU Study appeared first on Pharmaceutical Business review.

Original Article: Lilly’s solanezumab fails to meet objective in phase 2/3 DIAN-TU Study

NEXT ARTICLE

More From BioPortfolio on "Lilly’s solanezumab fails to meet objective in phase 2/3 DIAN-TU Study"

Quick Search

Relevant Topic

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...